Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice

@article{Chae2015BeneficialEO,
  title={Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice},
  author={Yu Na Chae and Tae-Hyoung Kim and Mi-kyung Kim and Chang-Yell Shin and Il-Hoon Jung and Yong Sung Sohn and Moon Ho Son},
  journal={PLoS ONE},
  year={2015},
  volume={10}
}
Although dipeptidyl peptidase 4 (DPP4) is an adipokine known to positively correlate with adiposity, the effects of pharmacological DPP4 inhibition on body composition have not been fully understood. This study was aimed to assess the effects of DPP4 inhibitors on adiposity for the first time in the established obese mice model. The weight loss effects of multiple DPP4 inhibitors were compared after a 4 week treatment in diet-induced obese mice. In addition, a 2 week study was performed to… 

Figures and Tables from this paper

Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models
TLDR
It is suggested that evogliptin treatment ameliorates fatty liver by increasing insulin sensitivity and suppressing lipogenesis and reduction in plasma non-esterified fatty acids supported the improvement of insulin resistance by evoglisptin treatment.
The Beneficial Effects of Sitagliptin, a Dipeptedyl Peptidase-4 (DPP-4) Inhibitor on Experimentally Induced Non-Alcoholic Fatty Liver Disease in Rats
TLDR
The results showed that the DPP4Is have the potential to favorably influence the course of NAFLD process and its complications, and has many beneficial effects including scavenging of free radicals, and enhancing the activity of antioxidant effects.
Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
TLDR
DPP4i may efficiently attenuate the pathogenesis of AMLN diet-induced NASH in mice by suppressing lipotoxicity-induced apoptosis, possibly by modulating hepatic DPP4 expression.
Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes
TLDR
This review summarizes the collected data concerning mechanism of action, clinical efficacy, and safety of evogliptin in improving glycemic control in patients with type 2 diabetes and finds that evoglisptin has benefits on insulin secretory and β-cell functions.
Effects of the Combination of Evogliptin and Leucine on Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice
TLDR
The results suggest that the combination of evogliptin and leucine may be beneficial for treating patients with type 2 diabetes and hepatic steatosis; however, further studies are needed to delineate the molecular mechanisms underlying the action of this combination.
Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation
TLDR
The results provide insights into the molecular mechanism of the direct inhibitory effect of the DPP-4 inhibitor evogliptin on pathological retinal neovascularization and suggest that its antiangiogenic effect could also render it beneficial for individuals with PDR.
FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats.
The impact of currently used oral antihyperglycemic drugs on dysfunctional adipose tissue
TLDR
Antihyperglycemic drugs of choice in obese individuals are those which cause maturation of adipocytes, improvement of secretion of protective adipokines, and redistribution of fat mass from visceral to subcutaneous depots.
...
...

References

SHOWING 1-10 OF 67 REFERENCES
Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
TLDR
This study is the first to suggest that DPP-4 inhibition augments postprandial lipid mobilization and oxidation, and may be explained by sympathetic activation rather than a direct effect on metabolic status.
Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
  • A. Dobrian, Q. Ma, J. Nadler
  • Biology, Medicine
    American journal of physiology. Endocrinology and metabolism
  • 2011
TLDR
Results indicate that sitagliptin has anti-inflammatory effects in adipose tissue and in pancreatic islets that accompany the insulinotropic effect.
Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures
TLDR
Systemic exenatide reduces body weight gain in normal, high-fat-fed rodents, a model that parallels human genetic variation and food consumption patterns, and may play a role in metabolic pathways mediating food intake.
Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
TLDR
Long-term linagliptin treatment reduced liver fat content in animals with diet-induced hepatic steatosis and insulin resistance, and may account for improved insulin sensitivity.
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
TLDR
DPP4 is a novel adipokine that may impair insulin sensitivity in an autocrine and paracrine fashion and release strongly correlates with adipocyte size, potentially representing an important source of DPP4 in obesity.
Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat–Fed Mice
TLDR
Although none of the therapies increased β-cell mass, only Ex-4–treated mice exhibited increased pancreatic mRNA transcripts for Irs2, Egfr, and Gck, highlighting significant differences between pharmacological administration of incretin receptor agonists and potentiation of endogenous GLP-1 and GIP via DPP-4 inhibition.
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
TLDR
Observations suggest that chronic deletion of DP-IV gene has significant impact on body weight control and energy homeostasis, providing validation ofDP-IV inhibition as a viable therapeutic option for the treatment of metabolic disorders related to diabetes and obesity.
...
...